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SUMMARY
To determine the prevalence of intestinal microsporidiosis in HIV-infected patients, we performed a prospective study of HIV-
infected patients with diarrheal illnesses in three US hospitals and examined an observational database of HIV-infected patients in
10 US cities. Among 737 specimens from the three hospitals, results were positive for 11 (prevalence 1.5%); seven (64%) acquired
HIV through male-to-male sexual contact, two (18%) through male-to-male sexual contact and injection drug use, and one (9%)
through heterosexual contact; one (9%) had an undetermined mode of transmission. Median CD4 count within six months of
diagnosis of microsporidiosis was 33 cells/µL (range 3 to 319 cells/µL). For the national observational database (n = 24,098), the
overall prevalence of microsporidiosis was 0.16%. Prevalence of microsporidiosis among HIV-infected patients with diarrheal
disease is low, and microsporidiosis is most often diagnosed in patients with very low CD4+ cell counts. Testing for microsporidia
appears to be indicated, especially for patients with very low CD4+ cell counts.
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Microsporidia, have been known for over a decade to cause
opportunistic infections in patients with human immunodeficiency virus
(HIV) infection. Enterocytozoon bieneusi is the most commonly
identified microsporidia in patients with HIV/AIDS. Microsporidiosis
usually produces diarrheal illness but can produce disseminated illness
in some persons depending upon the species involved5,13. Few reports
in the medical literature describe the prevalence of intestinal
microsporidiosis; those that do are not considered reliable and
generalizable2. One study, conducted before the widespread use of
highly active antiretroviral therapy (HAART), reported that
microsporidia accounted for 14.1% and 34.8% of cases of acute and
chronic diarrhea, respectively, in HIV-infected patients12. However,
since use of HAART has become widespread, very few data are available
on the prevalence of microsporidiosis in HIV-infected persons6.
One study suggests that the prevalence of infectious diarrhea (along
with AIDS opportunistic illnesses) has declined in recent years4. It is
not known whether the prevalence of microsporidiosis has declined as
well. Because clinical laboratory testing for microsporidia is not part
of the routine testing for ova and parasites, infection with microsporidia
is likely underrecognized. Therefore, active surveillance for infection
with microsporidia is necessary to estimate the true burden of this
infectious disease in patients with HIV and AIDS. In addition, the
sensitivity of testing for this infection could vary according to type of
test used15.
To determine the prevalence of intestinal microsporidiosis, we
performed a prospective study of HIV-infected patients with diarrheal
illnesses in three US hospitals that care for a high proportion of HIV-
infected persons in their cities. We also examined an observational
database involving medical record abstraction of HIV-infected patients
at participating healthcare facilities in 10 US cities (the Adult and
Adolescent Spectrum of HIV Disease Project).
METHODS
The study at three sites: CDC contracted with three sites (Denver,
New Orleans, and Seattle) participating in the Centers for Disease
Control and Prevention’s (CDC’s) Adult and Adolescent Spectrum of
HIV Disease project (ASD). The study was performed at three public
hospitals: Medical Center of Louisiana (formerly Charity Hospital of
New Orleans), New Orleans, Louisiana (1 January 1998 through 30
September 1999); a hospital in Seattle, Washington (1 February 1998
through 30 June 2000); and Denver Health Medical Center (formerly
Denver General Hospital), Denver, Colorado (30 March 1998 through
21 September 1999). These three hospitals performed supplemental
medical record abstraction and tested for microsporidia in HIV-infected
patients being evaluated for diarrheal illness. The study was approved
by the institutional review boards of Medical Center of Louisiana
(formerly Charity Hospital of New Orleans), New Orleans, Louisiana,
a hospital in Seattle, Washington, Denver Health Medical Center
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(formerly Denver General Hospital), Denver, Colorado and CDC.
At each participating hospital, consecutive diarrheal (loose) stool
specimens from HIV-infected patients sent to the hospital microbiology
laboratory were tested for microsporidia. One specimen was evaluated
for each patient (if multiple specimens were sent, the first specimen
was evaluated). The tests were performed on specimens that had been
sent to the hospital laboratory as part of the patient’s medical evaluation
for infectious diseases. Therefore, the physician’s decision to send a
stool specimen for evaluation of routine diarrheal pathogens was not
influenced by this study. Before this study, microsporidia testing was
not routinely performed on such specimens at the participating
hospitals. The Denver Health Medical Center and the Seattle hospital
used Moura’s quick-hot Gram chromotrope technique11; the Medical
Center of Louisiana used the modified trichrome blue stain14.
Stool specimens with positive test results for microsporidia were
sent to the CDC Division of Parasitic Diseases laboratory for
confirmation. Duplicate smears were made from each of the stool
specimens; one smear was stained with chromotrope 2R and one with
the quick-hot Gram chromotrope techniques. The stained smears were
examined under the oil immersion lens of an Olympus BX-60
microscope. Pinkish (in chromotrope 2R stained smear) or dark violet
(in quick-hot Gram chromotrope stained smear) spores confirmed
infection with microsporidia. After submitting for confirmation a
specimen with positive results, the participating hospital submitted
the next specimen with negative results to the CDC laboratory to
confirm that it was negative.
Patients whose specimens were negative for microsporidia were
assigned to a control group, but they could be reassigned to the
microsporidia group if a subsequent stool specimen revealed
microsporidia. If a patient’s specimen was positive for microsporidia,
then any further stool specimens from that patient were excluded from
the study for the remainder of that year.
The medical records of patients with positive test results were
reviewed using the appropriate (initial or follow-up) ASD form and a
supplemental medical record questionnaire that collected occupational
history, duration of diarrheal illness, recent antimicrobial prescriptions,
total lymphocyte count (if no CD4+ lymphocyte count was available
within six months of stool testing), and other pathogens identified from
the stool specimens with microsporidia.
At the end of the study, a quality assurance study was performed.
Duplicate smears were made from each of the stool specimens; one
smear was stained with chromotrope 2R and the other with the quick-
hot Gram chromotrope techniques. The stained smears were examined
under the oil immersion lens of an Olympus BX-60 microscope and
scored as positive if pinkish (in chromotrope 2R-stained smears) spores
with a vacuole, a median belt-like stripe, or both, were seen or if dark
violet (in quick-hot Gram chromotrope-stained smears) spores with a
vacuole, a median belt-like stripe, or both, were identified. To evaluate
the duration of diarrheal illness and to learn whether any patients had
died, the medical records of infected patients were reviewed six months
after the stool was tested.
Adult and Adolescent Spectrum of HIV Disease Project: ASD is a
longitudinal observational cohort study of HIV-infected persons at
participating health care facilities. Its methods have been previously
reported7. Briefly, for the initial medical record abstraction, records
for the entire year before patient enrollment in the study are reviewed;
information is then abstracted every six months until the patient dies
or is lost to follow-up. The initial medical record abstraction collects
patient information on demographics, mode of HIV exposure, any
previous occurrences of conditions listed in the AIDS surveillance case
definition3 and other conditions, medications prescribed, and CD4+
cell counts during the year before study inclusion. Cities participating
in ASD during the study periods were Atlanta, Georgia; Dallas, Houston,
and San Antonio, Texas; Denver, Colorado; Detroit, Michigan; Los
Angeles, California; New Orleans, Louisiana; New York City, New
York; Bayamon, Puerto Rico; and Seattle, Washington. Puerto Rico
was excluded from ASD analyses because physicians at the participating
site infrequently ordered stool testing for pathogens.
The prevalence of microsporidia among patients with infectious
diarrhea was also examined in the ASD database; however,
microsporidia were added as organism codes for data entry in 1997.
Cases recognized from the 3-city study (all confirmed at CDC) were
also included in the ASD database. However, the routine practice of
the ASD study includes the abstraction of a diagnosis (such as infectious
diarrhea), and the organism which was documented (by physician note
and laboratory test report) as causing the diagnosis without confirmation
by CDC.
RESULTS
The study at three ASD sites: Among 737 specimens screened,
results were positive for 11 (prevalence 1.5%). Of those with negative
results, 10 were selected to be controls. By city, the results were as
follows: New Orleans, eight cases among 512 specimens (prevalence
1.56%); Seattle, three cases among 159 specimens (prevalence 1.89%);
and Denver, zero cases among 66 specimens (prevalence 0%). Of these
11 patients with positive results, 64% were white, 27% were black,
9% were Asian/Pacific Islander, and 100% were male. Regarding the
mode of HIV transmission, 64% acquired HIV through male-to-male
sexual contact, 18% through male-to-male sexual contact and injection
drug use, and 9% through heterosexual contact; 9% had an
undetermined mode of transmission. The median age at diagnosis of
microsporidiosis was 34 years (range 29 to 46 years). Case and control
patients were not statistically (p > 0.05) different with regard to median
age, gender, race (white), and percentage with male-to-male sexual
contact as mode of HIV transmission. The median duration of diarrheal
illness for case- and control-patients overall at time of stool testing
was four weeks (range 0.5 to approximately 136 weeks). The median
CD4 count within six months of diagnosis was 33 cells/µL (range 3 to
319 cells/µL) for case patients and 348 cells/µL for the 10 control
patients. Nine of the case patients but only one of the control patients
had a CD4+ cell count below 100 cells/µL. During the six months
before diagnosis, 10 of the 11 case patients (91%) had been prescribed
a medication thought to have antimicrosporidial properties (seven
azithromycin, six fluconazole, four albendazole, two metronidazole,
and one octreotide; none received itraconazole, atovaquone, or
fumagillin. Recent occupational history was not available for six of
the case patients. Occupational history for the other five was as follows:
one was a farmer and woodcrafter, two were health professionals, one
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was an unemployed business professional, and one was an unemployed
computer consultant. One patient died within six months of diagnosis.
Adult and Adolescent Spectrum of HIV Disease Project: According
to the ASD database (including the three participating sites), 39 cases
of microsporidia-associated disease were found during 1998 through
2002 among 24,098 HIV-infected patients followed up during these
years [16 cases in 1998, 10 cases in 1999 (one of these was also a 1998
case), four cases in 2000, six cases in 2001, and four cases in 2002].
For nearly all of the cases, the species of microsporidia was not
specified. Infectious diarrhea was reported for 34 of these case patients;
other illness was reported for five. Twenty-seven (69%) of the case
patients were men who have sex with men (including two who also
had histories of injection drug use).
The overall prevalence of microsporidiosis in ASD was 0.16%; 0.23%
among patients with a CD4 count < 200 cells/µL, 0.33% among patients
with a CD4 count < 100 cells/µL, 0.26% among patients with male-to-
male sexual contact as mode of HIV transmission (not including men
who have sex with men and inject drugs), 0.20% among patients enrolled
at public hospitals (92.3% of all microsporidiosis case patients were
enrolled in ASD at public hospitals), and 0.11% among patients enrolled
in private practices or health care maintenance organizations.
The prevalence of microsporidiosis was highest in New Orleans
(0.31%). No cases were found in Los Angeles, Atlanta, Houston, Dallas,
San Antonio, Detroit, and New York City. The prevalence of
microsporidiosis among patients having a diagnosis of infectious
diarrhea from 1998 through 2002 was 0.88% and ranged from a high
of 1.15% in 1998 (1,392 patients with at least one diagnosis of infectious
diarrhea) to 0.53% in 2000 (759 patients with at least one diagnosis of
infectious diarrhea) (Fig. 1).
DISCUSSION
This study demonstrates that the prevalence of microsporidiosis is
low (1.5%) among HIV-infected patients for whom stool testing is
performed to evaluate diarrheal disease and that microsporidiosis is
most often diagnosed in patients with very low CD4+ cell counts. These
data reflect the prevalence of microsporidiosis in the United States in
a cohort of patients from three public health hospitals. The prevalence
may be lower in patients in other settings and could be higher in other
countries, especially developing countries where use of HAART may
be less common. Generalizations about exposure (such as may be
inferred from occupational history) are not available from our data
because of the low number of cases identified in our study.
Before we performed this study, anecdotal information had
suggested that microsporidiosis might be more common in New Orleans
than elsewhere. In addition, the prevalence in the overall 1998 through
2002 ASD database was higher at the New Orleans site. However, our
data do not support such a theory. Using a standard diagnostic approach
during this study time frame, we found that the prospective prevalence
in Seattle was similar to that found in New Orleans.
Our finding that most cases of microsporidiosis were diagnosed in
patients with a low CD4+ cell count <100 cells/µL is consistent with
the literature1,8-10. The difference between the median CD4+ cell
count in our case patients (33 cells/µL) and that in control patients
(348 cells/µL) was substantial. The finding of very low CD4+ cell count
in case patients is also consistent with similar findings from two other
published studies (KYAW et al., mean 37 cells/µL; LEDER et al.,
median 20 cells/µL)9,10. One of these studies also found that
microsporidiosis was associated with a history of swimming pool
exposure10. If confirmed in other studies, this finding could be
incorporated into opportunistic illness education programs for AIDS
patients.
Our study has several limitations. First, all three hospitals did not
use the same test method. According to the experience of one of the
authors, the prevalence rate might have been higher had the quick-hot
Gram chromotrope technique been used in all hospitals because with
this technique, the spores stain a dark violet color, making them easier
to recognize, especially when present in small numbers. Second, some
locations in the ASD database may have different practices that make
the likelihood of microsporidia testing less likely, especially since it is
not a routinely performed test in microbiology laboratories. Therefore,
microsporidia prevalence in the ASD database may underestimate the
true prevalence. Third, the diagnosis of microsporidia in stool was
confirmed only for the cases identified in the 3-city study, so it is
possible that misdiagnosis could have occurred, which would
overestimate the prevalence. We do not have information on the
laboratory practices at participating sites, which could have helped to
interpret why some ASD sites had no cases diagnosed in the 5-year
period examined. In addition, we did not identify large numbers of
cases, we did not have exposure histories, and we had minimal
occupational histories. Therefore, our study does not provide definitive
findings that would be helpful in identifying risk factors for infection.
Finally, the data may not be generalizable to all HIV-infected patients
with diarrheal illness because the data were derived only from patients
for whom stool testing was ordered by the physician.
We recommend consideration of microsporidiosis in any HIV-
infected patient with diarrheal illness, especially for patients with CD4+
cell counts < 50 cells/µL. Future studies could examine whether men
who have sex with men are at increased risk for microsporidiosis and
how microsporidia infections are acquired. This information could be
useful for creating prevention messages.
Fig. 1 - Prevalence of diagnosis of microsporidiosis in HIV-infected patients who had
infectious diarrhea and were enrolled in the Adult and Adolescent Spectrum of Disease Project
from 1998 through 2002 (n = 4427), and for the prospective study (Denver, Seattle, New
Orleans) (n = 737).
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RESUMO
Prevalência de microsporidiose intestinal em pacientes
infectados pelo HIV com diarréia nas principais cidades dos
Estados Unidos da América do Norte
Para determinar a prevalência de microsporidiose intestinal em
pacientes infectados pelo HIV foi realizado um estudo prospectivo em
três hospitais dos Estados Unidos da América do Norte (EUA) e
analizada uma base de dados nacional composta de dados coletados
de pacientes infectados pelo HIV em 10 cidades dos EUA. De um total
de 737 amostras de fezes de pacientes infectados pelo HIV que
apresentavam diarréia, amostras de 11 pacientes (prevalência de 1,5%)
foram positivas para microsporídios. Todos os positivos eram do sexo
masculino e, entre eles, sete (64%) pacientes adquiriram a infecção
pelo HIV através de relação homossexual, dois (18%) através de relação
sexual e drogas injetáveis e um (9%) através de contato heterosexual,
enquanto que em um paciente o modo de transmissão do HIV não foi
determinado. A contagem média de linfócitos CD4 realizada até seis
meses do diagnóstico de microsporidiose foi de 33 células/microlitro
(3 a 319 células/microlitro). A análise da base de dados nacional (n =
24.098) mostrou uma prevalência de microsporidiose de 0,16%. A
prevalência de microsporidiose em pacientes HIV-positivos com
diarréia é baixa. Entretando, como a microsporidiose é mais
frequentemente diagnosticada em pacientes com contagens de CD4
muito baixas, a indicação de pesquisa de microsporídios é justificada,
especialmente para estes pacientes.
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